Real-World Data Show Improved Survival With Adjuvant Immunotherapy in Melanoma

Source: OncLive, June 2020

The use of adjuvant immunotherapy in patients with resected stage IIIC melanoma resulted in improved survival benefit, according to real-world data from an early analysis of the National Cancer Database (NCDB), which were presented during a press program ahead of the 2020 AACR Virtual Annual Meeting II.1

Results showed that in the overall population, the 12-month survival rate of patients who received adjuvant immunotherapy was 93% versus 91% in those who did not; the 24-month survival rates were 83% versus 80%, respectively (P = .051).

When broken down by substage, the 24-month survival rates in patients with stage IIIC disease who received adjuvant immunotherapy had a statistically significant improvement in survival compared with those who did not receive the treatment, at 70% versus 59%, respectively (P <.01).

READ THE ORIGINAL FULL ARTICLE